clinical trial · NCT07013201
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
LEO Pharma·phase2·recruiting·n = 135
Palmoplantar PustulosisDelgocitinib creamVehicle cream
brief summary
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.
started
Sep 11, 2025
primary completion
Dec 14, 2026
completion
Dec 14, 2026
last updated
Oct 1, 2026
official title
A Proof-of-concept Phase 2a, Double-blind, 2-arm Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle During a 16-week Treatment Period in Adult Subjects With Mild to Severe Palmoplantar Pustulosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol